V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220022040 | 220017415 | 1.76 | null | Palliative (P) | 2017-01-26 | 2017-01-26 | Dasatinib | N | N | 220025121 | DASATINIB |
| 220022041 | 220006748 | null | 94.6 | Disease modification (D) | 2016-06-04 | 2016-06-04 | Rituximab | N | null | 220025945 | RITUXIMAB |
| 220022042 | 220006794 | 1.56 | 68.5 | Curative (C) | 2019-11-19 | 2019-11-19 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220026127 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022043 | 220013749 | 1.86 | 87 | Disease modification (D) | 2017-10-12 | 2017-10-13 | AML18 PILOT TRIAL | N | N | 220026128 | PILOT TRIAL |
| 220022044 | 220013773 | null | 59.7 | Disease modification (D) | 2018-01-14 | 2018-01-14 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 220026282 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022045 | 220006931 | 1.61 | 50 | Curative (C) | 2018-02-21 | 2018-02-21 | Rituximab | N | N | 220026587 | RITUXIMAB |
| 220022046 | 220007007 | 1.57 | null | Curative (C) | 2016-10-27 | 2016-11-13 | Alemtuz+Fludara+Melphalan RIC MUD | N | Y | 220026840 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022047 | 220007038 | 1.7 | null | Disease modification (D) | 2019-01-16 | 2019-04-05 | Dasatinib | 2 | N | 220026961 | DASATINIB |
| 220022048 | 220007067 | 0 | null | null | 2019-06-28 | 2019-06-29 | Rituximab | N | N | 220027042 | RITUXIMAB |
| 220022049 | 220007208 | 1.7 | 0 | Curative (C) | 2016-12-29 | 2016-12-29 | Dasatinib | null | null | 220027665 | DASATINIB |
| 220022050 | 220007216 | 1.6 | 64.9 | Curative (C) | 2015-04-02 | 2015-06-22 | AML18 PILOT TRIAL | Y | N | 220027691 | PILOT TRIAL |
| 220022051 | 220007218 | 1.72 | 0 | Curative (C) | 2016-07-14 | 2016-07-15 | Dasatinib | N | null | 220027703 | DASATINIB |
| 220022052 | 220007298 | null | 84.2 | null | 2015-07-26 | 2017-11-20 | AML18 PILOT TRIAL | N | null | 220028118 | PILOT TRIAL |
| 220022053 | 220014018 | 1.56 | null | null | 2013-10-06 | 2013-11-06 | Rituximab | N | N | 220028136 | RITUXIMAB |
| 220022054 | 220007320 | 1.64 | 73 | Curative (C) | null | 2016-11-10 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 220028203 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220022055 | 220007322 | 1.56 | 49.9 | Curative (C) | 2017-11-07 | 2017-11-19 | AML 18 TRIAL | Y | N | 220028206 | AML18 TRIAL |
| 220022056 | 220007340 | 1.7 | 83.3 | Curative (C) | 2018-01-14 | 2018-11-21 | Dasatinib | null | null | 220028292 | DASATINIB |
| 220022057 | 220014051 | 1.51 | null | Curative (C) | 2014-11-16 | 2014-11-25 | Cyclophosphamide+Fludara+TBI Allo | N | null | 220028341 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220022058 | 220014106 | 0 | 75 | Curative (C) | 2018-06-13 | 2018-07-28 | Methotrexate intrathecal | 2 | N | 220028812 | METHOTREXATE INTRATHECAL |
| 220022059 | 220007512 | 1.7 | 82 | Curative (C) | 2015-03-05 | 2015-03-05 | AML16 DA 2+5 | N | N | 220028990 | AML16 TRIAL |
| 220022060 | 220017706 | 1.58 | 60.3 | Curative (C) | 2018-04-27 | 2018-05-03 | FLAG | Y | null | 220028999 | FLAG |
| 220022061 | 220007549 | 0 | 89 | Disease modification (D) | 2017-02-08 | 2018-07-31 | Triple Intrathecal | 02 | N | 220029118 | TRIPLE INTRATHECAL |
| 220022062 | 220007596 | 1.68 | 94.2 | Disease modification (D) | 2019-05-05 | 2019-05-05 | Methotrexate intrathecal | 02 | N | 220029327 | METHOTREXATE INTRATHECAL |
| 220022064 | 220007623 | 1.56 | 83.8 | Curative (C) | 2014-12-25 | 2014-12-25 | Methotrexate intrathecal | N | N | 220029445 | METHOTREXATE INTRATHECAL |
| 220022065 | 220007640 | 1.85 | 83.1 | Curative (C) | 2016-10-05 | 2016-10-08 | FLAG | 2 | N | 220029470 | FLAG |
| 220022066 | 220007748 | 1.7 | 15.3 | Curative (C) | 2016-02-06 | 2016-12-30 | Methotrexate intrathecal | Y | N | 220029817 | METHOTREXATE INTRATHECAL |
| 220022067 | 220019770 | 1.64 | 74.1 | Curative (C) | 2017-04-01 | 2017-04-03 | Idarubicin+Tretinoin Spanish Crse2 | 99 | N | 220030114 | IDARUBICIN + TRETINOIN |
| 220022068 | 220007840 | 1.79 | 66.1 | null | 2015-11-21 | 2016-01-08 | Triple / Double Intrathecal Therapy | N | N | 220030144 | TRIPLE INTRATHECAL |
| 220022069 | 220007875 | 1.7 | 68.5 | Disease modification (D) | 2017-02-26 | 2018-03-13 | Triple / Double Intrathecal Therapy | N | N | 220030225 | TRIPLE INTRATHECAL |
| 220022070 | 220007930 | null | 88.8 | Disease modification (D) | 2001-06-14 | 2014-07-11 | Triple / Double Intrathecal Therapy | N | N | 220030353 | TRIPLE INTRATHECAL |
| 220022071 | 220014359 | 1.25 | 14.4 | Curative (C) | 2018-02-22 | 2018-02-22 | ATG + Busulfan + Fludarabine | N | null | 220030435 | ATG + BUSULFAN + FLUDARABINE |
| 220022072 | 220007962 | 1.94 | null | Curative (C) | 2015-07-03 | 2015-09-29 | BOSUTINIB | 99 | N | 220030471 | BOSUTINIB |
| 220022073 | 220007964 | 1.73 | 85 | Disease modification (D) | 2018-11-05 | 2018-11-12 | BOSUTINIB | 2 | N | 220030475 | BOSUTINIB |
| 220022074 | 220007970 | 1.58 | 0 | null | 2018-05-05 | 2018-05-18 | ATG + Busulfan + Fludarabine | null | N | 220030478 | ATG + BUSULFAN + FLUDARABINE |
| 220022075 | 220007982 | 1.78 | 5.7 | Curative (C) | 2014-07-28 | 2014-08-29 | BOSUTINIB | 02 | N | 220030497 | BOSUTINIB |
| 220022076 | 220008037 | 1.62 | 52.4 | Curative (C) | null | 2015-07-08 | Cyclophosphamide+Fludara+TBI Allo | 02 | null | 220030630 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220022077 | 220008089 | 1.83 | null | Curative (C) | 2014-12-27 | 2014-12-30 | FLAG | 02 | N | 220030766 | FLAG |
| 220022078 | 220008090 | 1.41 | null | Curative (C) | 2018-07-30 | 2018-09-22 | BOSUTINIB | Y | null | 220030779 | BOSUTINIB |
| 220022079 | 220008146 | 1.66 | 72 | Curative (C) | 2019-02-24 | 2019-07-07 | ATG + Busulfan + Fludarabine | 02 | N | 220030955 | ATG + BUSULFAN + FLUDARABINE |
| 220022080 | 220008172 | 1.86 | 67 | Curative (C) | 2013-11-07 | 2013-11-07 | ECX | 2 | N | 220031002 | ECX |
| 220022081 | 220017893 | null | 89.4 | null | 2018-07-03 | 2018-07-03 | IDARUBICIN | 02 | N | 220031027 | IDARUBICIN |
| 220022082 | 220008241 | 1.69 | 86.1 | Curative (C) | 2015-04-23 | 2015-05-07 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | Y | N | 220031302 | CISPLATIN + GEMCITABINE |
| 220022083 | 220008255 | 1.73 | 92.25 | Curative (C) | 2014-04-12 | 2016-01-11 | ECX | 02 | N | 220031392 | CISPLATIN + GEMCITABINE |
| 220022084 | 220008264 | 1.78 | 93 | Curative (C) | 2018-04-14 | 2018-04-22 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | N | N | 220031415 | IRINOTECAN + MDG |
| 220022085 | 220008323 | 1.77 | 74.3 | Curative (C) | 2013-09-02 | 2013-12-08 | ECX | 2 | null | 220031607 | FBC |
| 220022086 | 220008341 | 1.62 | null | null | 2017-06-21 | 2017-06-21 | ECX | null | null | 220031681 | PONATINIB |
| 220022087 | 220020949 | 1.66 | null | Curative (C) | 2019-05-31 | 2019-06-18 | Docetaxel | 02 | N | 220031813 | ECX |
| 220022088 | 220008421 | 1.67 | 89.4 | Curative (C) | null | 2017-07-24 | ECX | null | null | 220031947 | OXALIPLATIN + MDG |
| 220022089 | 220008437 | 1.73 | 79 | Curative (C) | 2018-06-17 | 2018-07-08 | PONATINIB | null | null | 220032025 | PONATINIB |
| 220022090 | 220008468 | 1.74 | 16.9 | Disease modification (D) | 2017-06-06 | 2017-06-06 | Cisplatin+Gemcitabine (gallbladder) | null | null | 220032105 | CISPLATIN + GEMCITABINE |